We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Indivior Plc | LSE:INDV | London | Ordinary Share | GB00BN4HT335 | ORD USD0.50 |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -6.00 | -0.39% | 1,514.00 | 1,518.00 | 1,525.00 | 1,540.00 | 1,496.00 | 1,540.00 | 517,964 | 16:35:12 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 1.09B | 2M | 0.0148 | 1,027.03 | 2.06B |
From Apr 2019 to Apr 2024
TIDMINDV
RNS Number : 5639V
Indivior PLC
06 November 2017
Indivior's Shaun Thaxter to present at the Jefferies London Healthcare Conference on November 15th
Slough, UK, and Richmond, VA, November 6th, 2017 - Indivior PLC (LON: INDV) today announced that Shaun Thaxter, CEO, will present at the Jefferies London Healthcare Conference on November 15th, 2017, at 9:20 a.m. local time, in London. Mark Crossley, CFO, and Jason Thompson, VP of Investor Relations, will also be in attendance. Thaxter will review Indivior's business and outlook. The presentation will be webcast live, and the broadcast and presentation materials will be available on the "Investors" section of Indivior's website (www.indivior.com) on November 15th, 2017.
About Indivior
Indivior is a global specialty pharmaceutical company with a 20-year legacy of leadership in patient advocacy and health policy while providing education on evidence-based treatment models that have revolutionized modern addiction treatment. The name is the fusion of the words individual and endeavour, and the tagline "Focus on you" makes the Company's commitment clear. Indivior is dedicated to transforming addiction from a global human crisis to a recognized and treated chronic disease. Building on its global portfolio of opioid dependence treatments, Indivior has a strong pipeline of product candidates designed to both expand on its heritage in this category and address other chronic conditions and co-occurring disorders of addiction, including alcohol use disorder and schizophrenia. Headquartered in the United States in Richmond, VA, Indivior employs more than 900 individuals globally and its portfolio of products is available in over 40 countries worldwide. Visit www.indivior.com to learn more.
Contact:
Jason Thompson
Vice President, Investor Relations
Tel: 804-423-8916 or jason.thompson@indivior.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCBJBITMBAMBMR
(END) Dow Jones Newswires
November 06, 2017 02:00 ET (07:00 GMT)
1 Year Indivior Chart |
1 Month Indivior Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
